Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
Sydney, Australia 25 March 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics. The agreement relates to Theragenics’ 134,000 square foot…